Marginal Zone Lymphoma Clinical Trials

181 clinical trials for Marginal Zone Lymphoma across international registries, including 59 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies — RECRUITING · PHASE1
• HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL — RECRUITING · PHASE2
• AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas — RECRUITING · PHASE1
• LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies — RECRUITING · PHASE1
• Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) — RECRUITING · PHASE1
• A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies — RECRUITING · PHASE1
• A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies — RECRUITING · PHASE1
• This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms — RECRUITING
• Allo HSCT Using RIC and PTCy for Hematological Diseases — RECRUITING · PHASE2
• A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies — RECRUITING · PHASE1
• Combating Cancer-Related Fatigue: A Personalized Supportive Care Program — RECRUITING · NA
• 64Cu-LLP2A for Imaging Hematologic Malignancies — RECRUITING · PHASE1
• Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma — RECRUITING · PHASE3
• Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader — RECRUITING · PHASE1
• Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma — RECRUITING · PHASE1
• SynKIR-310 for Relapsed/Refractory B-NHL — RECRUITING · PHASE1
• MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL — RECRUITING · PHASE2
• A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies — RECRUITING · PHASE1
• CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma — RECRUITING · PHASE2
• Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL — RECRUITING · PHASE2
• Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL — RECRUITING · PHASE2
• Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study — RECRUITING
• Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL) — RECRUITING · PHASE2
• CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies — RECRUITING · PHASE1
• Epco, Zanu, Ritux for R/R FL or MZL — RECRUITING · PHASE2
• A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas — RECRUITING · PHASE3
• Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. — RECRUITING · PHASE1
• Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas — RECRUITING · PHASE2
• Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas — RECRUITING · PHASE2
• A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL. — RECRUITING · PHASE2
• Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma — RECRUITING · PHASE4
• Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma — RECRUITING · PHASE2
• AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL) — RECRUITING · PHASE2
• Watch and Wait or Worry and Wait in Indolent Lymphoma — RECRUITING
• A Cohort Study in Newly Diagnosed MZL — RECRUITING
• Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma — RECRUITING
• A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies — RECRUITING · PHASE1
• SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry — RECRUITING
• Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) — RECRUITING · PHASE2
• Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL — RECRUITING · PHASE2
• Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma — RECRUITING · PHASE2
• Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma — RECRUITING
• CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas — RECRUITING · PHASE1
• Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial — RECRUITING · PHASE2
• Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma — RECRUITING · PHASE2
• Study to Assess Effectiveness and Safety of Zanubrutinib for Patients With Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP) — RECRUITING

Refine this search